APA (7th ed.) Citation

I. V. Kolyadina. (2021). Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: Updated results from the randomized clinical trials and their role in the clinical practice. ABV-press.

Chicago Style (17th ed.) Citation

I. V. Kolyadina. Ribociclib in the Treatment of HR+ HER2-negative Metastatic Breast Cancer: Updated Results from the Randomized Clinical Trials and Their Role in the Clinical Practice. ABV-press, 2021.

MLA (9th ed.) Citation

I. V. Kolyadina. Ribociclib in the Treatment of HR+ HER2-negative Metastatic Breast Cancer: Updated Results from the Randomized Clinical Trials and Their Role in the Clinical Practice. ABV-press, 2021.